President Kim Tae-han, who has led the company since 2011, retires

John Lim Appointed as New CEO of Samsung Bio View original image

[Asia Economy Reporter Seo So-jeong] Samsung Biologics announced on the 8th that Vice President John Lim (photo) has been appointed as the new CEO. Kim Tae-han, who has led the company since its establishment in 2011, will step down as CEO.


New CEO Lim holds a master's degree in Chemical Engineering from Stanford University and an MBA from Northwestern University. He has held positions such as head of production, sales, development, and Chief Financial Officer (CFO) at Roche and Genentech. He joined Samsung Biologics in September 2018 and is currently overseeing operations related to Plant 3.


Samsung Biologics expects CEO Lim to accelerate the globalization and growth of Samsung's bio and pharmaceutical business based on his extensive experience at global bio-pharmaceutical companies.


A Samsung Biologics official said, "CEO Lim has achieved results such as securing contract manufacturing volumes of biopharmaceuticals from global pharmaceutical companies by managing Plant 3 at Samsung Biologics," adding, "We expect him to maintain stability and continue innovation and growth amid the worsening global business environment and the COVID-19 crisis."



Kim Tae-han, who has led the company since its establishment, will retire. It is known that Kim stepped down from the CEO position to facilitate generational change and nurture his successor. Samsung Biologics is also expected to finalize and announce the regular executive personnel appointments for 2021, including vice presidents, soon.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing